StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)

Close on Nov 18, 2026Market cap $291.16MP/E –Yield –

SAB Biotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

SAB Biotherapeutics's price to sales ratio was 11.9× on Apr 30, 2025, against 17.7× a year earlier. Over the last 4 years it ranged from 0.6× to 23.1×, with a median of 6.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 202511.9×−11.2
2024Dec 31, 202423.1×+7.6
2023Dec 29, 202315.5×+14.1
2022Dec 30, 20221.4×+0.5
2021Dec 31, 20210.8×–

More SAB Biotherapeutics figures

See a number that looks wrong?